Vorinostat Plus Bortezomib Active in Refractory Myeloma

Share this content:
The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are refractory to novel treatment strategies.
The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are refractory to novel treatment strategies.

The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are refractory to novel treatment strategies, a study published in the journal Clinical Lymphoma, Myeloma, & Leukemia has shown.1 This regimen may potentially offer a new therapeutic option for this difficult-to-treat population.

For the multicenter, open-label, single-arm, phase 2b study, researchers sought to assess the efficacy and tolerability of vorinostat with bortezomib in patients who were refractory to novel multiple myeloma therapies.

Investigators enrolled adult patients who had received 2 or more prior regimens, including 1 prior bortezomib-containing regimen and at least 1 dose of regimen containing an immunomodulatory agent, such as thalidomide, lenalidomide, and pomalidomide.

All patients received bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 plus vorinostat 400 mg/day orally on days 1 to 14 of each 21-day cycle. Participants with progressive disease after 2 cycles of no change after 4 cycles were eligible to receive dexamethasone 20 mg orally on day of and day after each bortezomib dose.

Results showed that the objective response rate was 11.3% (95% CI, 6.6 - 17.7) and the median duration of response was 211 days (range, 64 - 550).

Researchers found that median overall survival was 11.2 months (95% CI, 8.5 - 14.4) and 32% of patients were alive at 2 years.

In terms of safety, the most commonly reported adverse events associated with treatment were thrombocytopenia (69.7%), nausea (57.0%), diarrhea (53.5%), anemia (52.1%), and fatigue (48.6%). Investigators deemed the overall safety profile to be consistent with bortezomib and vorinostat.

RELATED: PomCyDex May Be an Effective Oral Regimen for Refractory Myeloma

Vorinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma. It is under investigation for the treatment of patients with multiple myeloma. Panobinostat was the first HDAC inhibitor approved by the U.S. Food and Drug Administration for multiple myeloma.

Reference

  1. Siegel DS, Dimopoulos M, Jagannath S, et al. VANTAGE 095: An international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma [published online ahead of print March 4, 2016]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2016.02.042.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters